Sumitomo Mitsui DS Asset Management Company Ltd Sells 4,608 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Sumitomo Mitsui DS Asset Management Company Ltd lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 77.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,343 shares of the medical research company's stock after selling 4,608 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Charles River Laboratories International were worth $202,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Rothschild Investment LLC raised its holdings in shares of Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after acquiring an additional 144 shares during the last quarter. Optiver Holding B.V. purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $37,000. GeoWealth Management LLC boosted its stake in shares of Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after buying an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $48,000. Finally, Tortoise Investment Management LLC boosted its stake in shares of Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after buying an additional 115 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

CRL traded up $4.58 on Tuesday, hitting $158.48. The company's stock had a trading volume of 752,391 shares, compared to its average volume of 1,029,346. The company's 50 day simple moving average is $142.30 and its 200-day simple moving average is $152.12. The firm has a market cap of $7.78 billion, a P/E ratio of -243.82, a price-to-earnings-growth ratio of 5.21 and a beta of 1.49. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same period last year, the firm earned $2.27 EPS. Charles River Laboratories International's revenue for the quarter was down 2.7% on a year-over-year basis. Analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president directly owned 19,513 shares of the company's stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. The Goldman Sachs Group downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price on the stock in a research note on Thursday, May 8th. Wall Street Zen lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Mizuho decreased their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).